• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

CIS Bio to license tracer technology

Article

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new technetium-labeled compounds. The agreementincludes rights for a nuclear cardiology agent that shows promisein imaging myocardial ischemia and infarction, according to thecompany.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.